Entecavir, sold under the brand name Baraclude, is an antiviral medication used to treat hepatitis B virus (HBV) infection. It works by inhibiting HBV DNA polymerase, preventing viral replication. Entecavir is taken orally as a tablet or solution and is considered a first-line treatment for chronic HBV. In patients with both HIV/AIDS and HBV, it should be used in combination with antiretroviral therapy to prevent the development of resistance.
Parent: Entecavir
Parent: Entecavir / Entecavir Monohydrate
![2-amino-9-((3aS,4S,6S,6aR)-3a,6-dihydroxyhexahydro-1H-cyclopenta[c]furan-4-yl)-3H-purin-6(9H)-one](https://veeprho.com/wp-content/uploads/2026/05/2-amino-9-3aS4S6S6aR-3a6-dihydroxyhexahydro-1H-cyclopentacfuran-4-yl-3H-purin-69H-one-NA-VE0028736.png "2-amino-9-((3aS,4S,6S,6aR)-3a,6-dihydroxyhexahydro-1H-cyclopenta[c]furan-4-yl)-3H-purin-6(9H)-one")
Parent: Entecavir
![2-amino-9-[(1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-8-methoxy-1H-purin-6-one](https://veeprho.com/wp-content/uploads/2026/05/2-amino-9-1R3S4R-4-hydroxy-3-hydroxymethyl-2-methylidenecyclopentyl-8-methoxy-1H-purin-6-one-2203740-23-0-VE0014957-fd5f.png "2-amino-9-[(1R,3S,4R)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-8-methoxy-1H-purin-6-one")
Parent: Entecavir
Impurities in Entecavir can arise due to synthesis processes, degradation, or storage conditions. Regulatory authorities like the FDA, ICH, and EMA enforce strict impurity limits to ensure the drug’s safety and efficacy.
Process-Related Impurities
• Unreacted intermediates from chemical synthesis
• Residual solvents (e.g., methanol, ethanol, dichloromethane)
• By-products from synthetic reactions
Degradation Impurities
• Oxidation by-products due to exposure to oxygen or light
• Hydrolysis impurities from moisture exposure
• Thermal degradation products under high temperatures
Elemental Impurities
• Heavy metals from catalysts used in synthesis**
• Trace levels of lead, arsenic, cadmium, mercury**
Analytical Techniques for Impurity Detection
• High-Performance Liquid Chromatography (HPLC)
• Gas Chromatography (GC)
• Mass Spectrometry (MS)
• Fourier-Transform Infrared Spectroscopy (FT-IR)
Precautions when taking Entecavir include:
• Regular liver function monitoring to assess HBV response and detect potential liver complications.
• HIV testing before starting treatment, as using Entecavir alone in an undiagnosed HIV-positive patient may lead to resistance.
• Monitoring for signs of lactic acidosis, particularly in patients with liver disease.
• Avoid alcohol as it can further damage the liver.
Both Entecavir and Tenofovir are effective first-line treatments for chronic HBV, but:
• Tenofovir has a higher barrier to resistance, making it preferred for patients at risk of drug resistance.
• Entecavir may be preferred in patients with kidney impairment, as Tenofovir has been linked to renal toxicity and bone loss.
The duration of Entecavir treatment depends on the patient’s condition:
• For HBeAg-positive patients, treatment is typically continued until at least 12 months after HBeAg seroconversion.
• For HBeAg-negative patients, long-term therapy is often required, sometimes lifelong.
• Stopping Entecavir too early may lead to viral relapse.
Yes, lactic acidosis is a rare but serious side effect of Entecavir. Symptoms include fatigue, muscle pain, difficulty breathing, nausea, and abdominal pain. It occurs due to mitochondrial toxicity and is more common in patients with liver disease.
